GBA1 and Gaucher disease: The first ERT for Gaucher disease was approved by the U.S. Food and Drug Administration (FDA) in 1991 using the glucocerebrosidase (GC) enzymes purified from human placenta (Ries, 2017) and was later replaced by imiglucerase, a recombinant human protein that is now broadly used in ERT.